NASDAQ:MESO Mesoblast (MESO) Stock Forecast, Price & News $1.20 +0.01 (+0.84%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$1.16▼$1.2550-Day Range$1.19▼$4.1552-Week Range$1.16▼$5.12Volume61,369 shsAverage Volume149,983 shsMarket Capitalization$195.41 millionP/E RatioN/ADividend YieldN/APrice Target$7.13 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Mesoblast MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside493.8% Upside$7.13 Price TargetShort InterestHealthy0.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector286th out of 965 stocksBiological Products, Except Diagnostic Industry44th out of 157 stocks 4.1 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.13, Mesoblast has a forecasted upside of 493.8% from its current price of $1.20.Amount of Analyst CoverageMesoblast has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.58% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently decreased by 15.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 2.6 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mesoblast this week, compared to 1 article on an average week.Search Interest11 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.60% of the stock of Mesoblast is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to remain at ($0.47) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mesoblast (NASDAQ:MESO) StockMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comJane Bell AM Appointed Chair of Mesoblast Audit and Risk CommitteeSeptember 25, 2023 | americanbankingnews.comMesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of "Hold" by BrokeragesOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 21, 2023 | markets.businessinsider.comAnalyst Expectations for Mesoblast's FutureSeptember 2, 2023 | seekingalpha.comMesoblast Limited (MESO) Q4 2023 Earnings Call TranscriptSeptember 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Mesoblast (MESO)August 31, 2023 | markets.businessinsider.comWilliam Blair Reaffirms Their Hold Rating on Mesoblast (MESO)August 31, 2023 | markets.businessinsider.comAnalyst Bullish On Cell Therapy Player Mesoblast, But Cuts Price TargetOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.August 31, 2023 | finance.yahoo.comMesoblast Limited (NASDAQ:MESO) Q4 2023 Earnings Call TranscriptAugust 30, 2023 | fool.com.auMesoblast share price rises as losses narrow in FY23August 30, 2023 | finance.yahoo.comMesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023August 25, 2023 | finance.yahoo.comDecoding Mesoblast Ltd's Performance: A Deep Dive into the MetricsAugust 25, 2023 | finance.yahoo.comIs Mesoblast Ltd (MESO) a Hidden Value Trap? Unpacking the Risks and RewardsAugust 8, 2023 | finance.yahoo.comWhy Shares of Mesoblast Are Down MondayAugust 6, 2023 | msn.comDr Boreham’s Crucible: Oh, Mesoblast! You were the Chosen One!August 5, 2023 | marketwatch.comMesoblast ADSs Plunge Premarket on Latest FDA Rejection >MESOAugust 5, 2023 | markets.businessinsider.comMesoblast Shares Tumble As FDA Strikes Out Cell Therapy Application For Children Again, Requires Additional TrialAugust 4, 2023 | marketwatch.comADRs End Mostly Higher, Missfresh and Mesoblast Trade ActivelyAugust 4, 2023 | finance.yahoo.comNikola's Abrupt CEO Transition, Carl Icahn Led Icahn Enterprises Cuts Dividend Payout, FDA Rejects Mesoblast's Cell Therapy For Kids: Today's Top StoriesAugust 4, 2023 | finance.yahoo.comWhy Shares of Mesoblast Are Plunging FridayAugust 4, 2023 | afr.comASX closes higher but ends the week down 1pcAugust 4, 2023 | finance.yahoo.comUPDATE 1-Mesoblast shares tank after US FDA rejects cell therapy for childrenAugust 3, 2023 | au.finance.yahoo.comMESO - Mesoblast LimitedAugust 2, 2023 | fool.com.auIs no FDA news bad news for Mesoblast shares?August 2, 2023 | msn.comMesoblast Ltd - ADR (MESO) Price Target Increased by 13.98% to 4.64August 1, 2023 | fool.com.auWhy Credit Corp, Mesoblast, Talon Energy, and Weebit Nano shares are fallingSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address MESO Company Calendar Last Earnings8/30/2023Today10/03/2023Next Earnings (Estimated)11/28/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees83Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.13 High Stock Price Forecast$17.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+493.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,890,000.00 Net Margins-1,061.43% Pretax Margin-1,094.53% Return on Equity-16.32% Return on Assets-12.26% Debt Debt-to-Equity Ratio0.20 Current Ratio1.95 Quick Ratio1.95 Sales & Book Value Annual Sales$7.50 million Price / Sales26.05 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book0.39Miscellaneous Outstanding Shares162,841,000Free Float132,227,000Market Cap$195.41 million OptionableOptionable Beta3.32 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 66)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director Comp: $726.28kDr. Eric A. Rose M.D. (Age 72)Chief Medical Officer & Exec. Director Comp: $614.91kMr. Andrew Chaponnel B.Com.Interim Chief Fin. OfficerMs. Dagmar Rosa-Bjorkeson M.B.A. (Age 59)M.S., Chief Operating Officer Mr. Peter T. Howard B.Sc. (Age 55)L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec. Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster M.B.A. (Age 46)MS, BSc, MBA, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., Bsc, MMS, MBA, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company Sec.More ExecutivesKey CompetitorsInnate PharmaNASDAQ:IPHAFate TherapeuticsNASDAQ:FATESutro BiopharmaNASDAQ:STROTenaya TherapeuticsNASDAQ:TNYAPoseida TherapeuticsNASDAQ:PSTXView All CompetitorsInstitutional OwnershipWells Fargo & Company MNBought 18,747 shares on 8/15/2023Ownership: 0.032%Citadel Advisors LLCSold 24,600 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Bought 57,252 shares on 8/11/2023Ownership: 0.086%Simplex Trading LLCSold 1,400 shares on 8/4/2023Ownership: 0.000%Signaturefd LLCBought 7,230 shares on 8/1/2023Ownership: 0.007%View All Institutional Transactions MESO Stock - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks. What is Mesoblast's stock price forecast for 2023? 6 brokerages have issued 1-year target prices for Mesoblast's shares. Their MESO share price forecasts range from $1.50 to $17.00. On average, they expect the company's share price to reach $7.13 in the next year. This suggests a possible upside of 493.8% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts. How have MESO shares performed in 2023? Mesoblast's stock was trading at $2.91 at the start of the year. Since then, MESO stock has decreased by 58.8% and is now trading at $1.20. View the best growth stocks for 2023 here. Are investors shorting Mesoblast? Mesoblast saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 941,200 shares, a decrease of 15.2% from the August 31st total of 1,110,000 shares. Based on an average trading volume of 522,000 shares, the days-to-cover ratio is presently 1.8 days. View Mesoblast's Short Interest. When is Mesoblast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023. View our MESO earnings forecast. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) released its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $2 million. Mesoblast had a negative trailing twelve-month return on equity of 16.32% and a negative net margin of 1,061.43%. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV). When did Mesoblast IPO? (MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. What is Mesoblast's stock symbol? Mesoblast trades on the NASDAQ under the ticker symbol "MESO." How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mesoblast's stock price today? One share of MESO stock can currently be purchased for approximately $1.20. How much money does Mesoblast make? Mesoblast (NASDAQ:MESO) has a market capitalization of $195.41 million and generates $7.50 million in revenue each year. The company earns $-81,890,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. How can I contact Mesoblast? Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030. This page (NASDAQ:MESO) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.